10 Best Performing Affordable Stocks Under $40
On January 14, Liz Ann Sonders from Charles Schwab appeared on a CNBC Television interview to discuss the market volatility, broadening out themes, and more.
Emergent Biosolutions Inc. (EBS)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Jain Global LLC Bobby Jain | 942,691 | $11,651,661 | +86% | 0.06% |
| 2. | Prescott Group Capital Management Phil Frohlich | 772,771 | $9,551,450 | 0.89% | |
| 3. | Marshall Wace LLP Paul Marshall And Ian Wace | 743,455 | $9,189,104 | -19% | 0.01% |
| 4. | D E Shaw D. E. Shaw | 723,217 | $8,938,962 | +126% | 0% |
| 5. | Renaissance Technologies Jim Simons | 577,147 | $7,133,537 | +12% | 0.01% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $5.83 | 60,000 | $349,800.00 | 342,500 | 2025-05-13 | Filing | |
| $37.46 | 3,000 | $112,380.00 | 39,919 | 2021-11-15 | Filing | |
| $27.08 | 98 | $2,653.84 | 41,444 | 2015-06-01 | Filing | |
| $19.08 | 749 | $14,290.92 | 103,373 | 2013-11-30 | Filing | |
| $12.07 | 800 | $9,656.00 | 96,011 | 2013-05-31 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $8.44 | 4,000 | $33,760.00 | 62,681 | 2026-04-01 | Filing | |
| $11.90 | 14,884 | $177,086.86 | 98,417 | 2025-12-05 | Filing | |
| $12.11 | 7,100 | $85,990.23 | 98,417 | 2025-12-05 | Filing | |
| $10.54 | 17,801 | $187,622.54 | 119,858 | 2025-11-10 | Filing | |
| $10.00 | 8,552 | $85,520.00 | 88,980 | 2025-11-07 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 307,880 | $2,555,406 | 1.33% | |
| 2. | 106,700 | $885,610 | 0.06% | |
| 3. | 65,754 | $545,758 | 0.03% | |
| 4. | 65,268 | $541,724 | 0.01% | |
| 5. | 56,455 | $468,577 | 0% |
News See All
Emergent BioSolutions Inc. (NYSE:EBS) Q3 2025 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Q3 2025 Emergent BioSolutions Inc. Earnings Conference Call.
Emergent BioSolutions Inc. (NYSE:EBS) Q2 2025 Earnings Call Transcript
Operator: Good afternoon, everyone. Thank you for joining today as Emergent discusses their operational and financial results for the Second Quarter of 2025.
Emergent BioSolutions Inc. (NYSE:EBS) Q1 2025 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to the First Quarter 2025 Emergent BioSolutions, Inc. Earnings Conference Call.
Emergent BioSolutions Inc. (NYSE:EBS) Q4 2024 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to Emergent BioSolutions Inc. Fourth Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Emergent BioSolutions Inc. (NYSE:EBS) Q3 2024 Earnings Call Transcript
Operator: Thank you for standing by. My name is Kris and I will be your conference operator today. At this time, I would like to welcome everyone to the Q3 2024 Emergent BioSolutions Inc.
12 Best Performing Cheap Stocks in 2024
As we step into the final quarter of 2024, the financial markets continue to navigate a complex terrain shaped by a mix of optimism and uncertainty.
Emergent BioSolutions Inc. (NYSE:EBS) Q2 2024 Earnings Call Transcript
Operator: Good afternoon, everyone. I'm the operator for today's call. Thank you for joining today as Emergent discusses their Operational and Financial Results for the Second Quarter of 2024.
Emergent BioSolutions Inc. (NYSE:EBS) Q1 2024 Earnings Call Transcript
Emergent BioSolutions Inc. beats earnings expectations. Reported EPS is $0.59, expectations were $-0.86. Emergent BioSolutions Inc.
5 Best Biotech Penny Stocks to Invest In
Ocean Biomedical, Inc. (NASDAQ:OCEA) is a biopharmaceutical company that focuses on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases.
Hedge Fund Resource Center